Thyrocare Technologies · NSE: THYROCARE · BSE: 539871

Q2 FY25 results · Jul–Sep 2024

Thyrocare Technologies reported revenue from operations of ₹177.36 crore (up 19.8% from Q2 FY24) and net profit of ₹26.42 crore (up 30.0% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	177.36	148.00	+19.8%	156.91	+13.0%
Other income	2.60	2.17	+20.0%	3.62	−28.0%
Total income	179.96	150.17	+19.8%	160.53	+12.1%
Profit before share of associates & JVs and tax	37.06	27.91	+32.8%	33.91	+9.3%
Share of profit/(loss) of associates & JVs	(0.29)	0.36		(0.36)
Net profit for the period	26.42	20.33	+30.0%	23.94	+10.4%
Attributable to shareholders of the company	26.67	20.34	+31.1%	24.17	+10.3%
EPS, basic (₹)	4.99	3.84	+29.9%	4.52	+10.4%
Net margin (%)	14.9	13.7		15.3

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY25	Q2 FY24	YoY	Q1 FY25	QoQ
Revenue from operations	163.05	136.29	+19.6%	143.63	+13.5%
Other income	2.12	1.82	+16.5%	3.17	−33.1%
Total income	165.17	138.11	+19.6%	146.80	+12.5%
Profit before tax	40.34	28.13	+43.4%	35.14	+14.8%
Net profit for the period	29.59	20.29	+45.8%	25.15	+17.6%
EPS, basic (₹)	5.59	3.83	+45.8%	4.75	+17.6%
Net margin (%)	18.1	14.9		17.5

Consolidated

Filed with BSE: 06 Nov 2024, 10:08 IST
Board meeting: 23 Oct 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 06 Nov 2024, 10:08 IST
Board meeting: 23 Oct 2024
Period: 01 Jul 2024 to 30 Sep 2024
Review status: Unaudited
Source: XBRL filing on BSE